VERSO BIOSENSE R&D LIMITED

Active Abingdon

Activities of other holding companies n.e.c.

0 employees website.com
Life sciences and medical technology Activities of other holding companies n.e.c.
V

VERSO BIOSENSE R&D LIMITED

Activities of other holding companies n.e.c.

Founded 26 Nov 2015 Active Abingdon, United Kingdom 0 employees website.com
Life sciences and medical technology Activities of other holding companies n.e.c.

Previous Company Names

VIVOPLEX ANIMAL HEALTH LIMITED 17 May 2019 — 1 May 2023
VIVOPLEX INDUSTRIAL LIMITED 6 Oct 2017 — 17 May 2019
VIVOPLEX LIMITED 26 Nov 2015 — 6 Oct 2017
Accounts Submitted 30 Sept 2025 Next due 30 Sept 2026 4 months remaining
Confirmation Submitted 19 Dec 2025 Next due 9 Dec 2026 7 months remaining
Net assets £-11K £2K 2024 year on year
Total assets £80 £823K 2024 year on year
Total Liabilities £11K £821K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Milton Park Milton Abingdon Oxfordshire OX14 4RZ United Kingdom

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for VERSO BIOSENSE R&D LIMITED (09890252), an active life sciences and medical technology company based in Abingdon, United Kingdom. Incorporated 26 Nov 2015. Activities of other holding companies n.e.c.. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2016–2024)

Cash in Bank

£70.00

Increased by £52.00 (+289%)

Net Assets

-£11.15k

Decreased by £1.83k (-20%)

Total Liabilities

£11.23k

Decreased by £821.44k (-99%)

Turnover

N/A

Employees

N/A

Debt Ratio

14036%

Increased by 13935 (+13797%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Grants 1

Investors (0)

No investor information available

Officers

Officers

1 active 2 resigned
Status
Christopher John DicksonDirectorBritishEngland6626 Nov 2015Active

Shareholders

Shareholders (1)

Vivoplex Medical Limited
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased
Notified 29 Aug 2017
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent

Charles Edward Dickson

Ceased 29 Aug 2017

Ceased

Group Structure

Group Structure

VERSO BIOSENSE R&D LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
19 Dec 2025Confirmation StatementConfirmation statement made on 25 Nov 2025 with no updates
11 Dec 2025OfficersTermination of Nicholas Stephen Macklon as director on 25 Nov 2025
11 Dec 2025OfficersTermination of Hywel Morgan as director on 11 Jun 2024
26 Nov 2025Persons With Significant ControlChange to Verso Biosense Group Limited as a person with significant control on 29 Aug 2017
30 Sept 2025AccountsAnnual accounts made up to 31 Dec 2024
19 Dec 2025 Confirmation Statement

Confirmation statement made on 25 Nov 2025 with no updates

11 Dec 2025 Officers

Termination of Nicholas Stephen Macklon as director on 25 Nov 2025

11 Dec 2025 Officers

Termination of Hywel Morgan as director on 11 Jun 2024

26 Nov 2025 Persons With Significant Control

Change to Verso Biosense Group Limited as a person with significant control on 29 Aug 2017

30 Sept 2025 Accounts

Annual accounts made up to 31 Dec 2024

Recent Activity

Latest Activity

Confirmation statement made on 25 Nov 2025 with no updates

4 months ago on 19 Dec 2025

Termination of Nicholas Stephen Macklon as director on 25 Nov 2025

4 months ago on 11 Dec 2025

Termination of Hywel Morgan as director on 11 Jun 2024

4 months ago on 11 Dec 2025

Change to Verso Biosense Group Limited as a person with significant control on 29 Aug 2017

5 months ago on 26 Nov 2025

Annual accounts made up to 31 Dec 2024

7 months ago on 30 Sept 2025